See more : Ataa Educational Company (4292.SR) Income Statement Analysis – Financial Results
Complete financial analysis of Orient Pharma Co., Ltd. (4166.TWO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Orient Pharma Co., Ltd., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Group 107 Ltd. (G107.TA) Income Statement Analysis – Financial Results
- Ryerson Holding Corporation (RYI) Income Statement Analysis – Financial Results
- Nu Ride Inc. (NRDE) Income Statement Analysis – Financial Results
- Pricer AB (publ) (PRIC-B.ST) Income Statement Analysis – Financial Results
- Amesite Inc. (AMST) Income Statement Analysis – Financial Results
Orient Pharma Co., Ltd. (4166.TWO)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.oppharma.com
About Orient Pharma Co., Ltd.
Orient Pharma Co., Ltd. engages in the research and development, manufacturing, and sales of drugs in Taiwan and internationally. The company develops anti-psychotics and psychostimulants, as well as drugs for treating Parkinson's and Alzheimer's diseases; and products for the treatment of sialorrhea, tuberculosis, and attention deficit hyperactivity disorder. It is also developing drug delivery technologies, such as multi-stages-controlled release technology, trans-dermal patches, oral disintegrating tablets, sustained release technology, and micro granules. The company was founded in 2008 and is based in Taipei, Taiwan.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 889.91M | 511.86M | 463.34M | 412.01M | 353.54M |
| Cost of Revenue | 421.25M | 356.51M | 320.67M | 336.86M | 339.85M |
| Gross Profit | 468.67M | 155.35M | 142.67M | 75.15M | 13.69M |
| Gross Profit Ratio | 52.66% | 30.35% | 30.79% | 18.24% | 3.87% |
| Research & Development | 99.90M | 129.25M | 219.72M | 183.94M | 153.62M |
| General & Administrative | 67.36M | 57.62M | 48.39M | 49.48M | 57.58M |
| Selling & Marketing | 273.65M | 10.22M | 8.05M | 8.49M | 7.86M |
| SG&A | 341.01M | 67.83M | 56.45M | 57.97M | 65.43M |
| Other Expenses | 0.00 | 6.91M | 28.58M | 6.08M | 0.00 |
| Operating Expenses | 444.35M | 197.09M | 276.16M | 241.91M | 211.17M |
| Cost & Expenses | 865.59M | 553.60M | 596.83M | 578.77M | 551.02M |
| Interest Income | 1.68M | 1.09M | 518.00K | 410.00K | 0.00 |
| Interest Expense | 13.90M | 7.37M | 5.70M | 5.38M | 4.93M |
| Depreciation & Amortization | 135.57M | 69.10M | 65.18M | 66.57M | 54.69M |
| EBITDA | 172.40M | 35.37M | -39.21M | -93.70M | -130.34M |
| EBITDA Ratio | 19.37% | 6.91% | -8.46% | -22.74% | -42.62% |
| Operating Income | 27.75M | -33.73M | -104.39M | -160.27M | -205.37M |
| Operating Income Ratio | 3.12% | -6.59% | -22.53% | -38.90% | -58.09% |
| Total Other Income/Expenses | -4.83M | 629.00K | 23.40M | 1.11M | 2.96M |
| Income Before Tax | 22.92M | -41.11M | -110.09M | -165.65M | -202.41M |
| Income Before Tax Ratio | 2.58% | -8.03% | -23.76% | -40.20% | -57.25% |
| Income Tax Expense | 636.00K | -12.35M | -7.44M | 5.73M | 1.39M |
| Net Income | 22.29M | -28.76M | -102.65M | -171.38M | -201.03M |
| Net Income Ratio | 2.50% | -5.62% | -22.15% | -41.59% | -56.86% |
| EPS | 0.10 | -0.15 | -0.55 | -1.01 | -1.29 |
| EPS Diluted | 0.10 | -0.15 | -0.55 | -1.01 | -1.29 |
| Weighted Avg Shares Out | 223.04M | 187.00M | 187.01M | 169.40M | 156.03M |
| Weighted Avg Shares Out (Dil) | 223.04M | 187.00M | 187.01M | 169.40M | 156.03M |
Source: https://incomestatements.info
Category: Stock Reports